3 active not recruiting. 2 Phase 3, 1 Phase 2.
By phase and status
Follow ARDT: new trials by email Literature Review of ARDT trials Research Report on ARDT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
[177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11 - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Active not recruiting | 63 | 2023-05-05 | 2026-03-23 |
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms | Phase 3 | Active not recruiting | 469 | 2021-06-15 | 2026-09-11 |
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms | Phase 3 | Active not recruiting | 1140 | 2021-06-09 | 2026-06-08 |
Conditions studied
Prostatic Neoplasms (2)
Sponsors
Novartis Pharmaceuticals (3)
Countries
Austria (2) · Belgium (2) · Canada (2) · China (2) · Czechia (2) · France (2) · Germany (2) · Netherlands (2) · Poland (2) · Spain (2) · Sweden (2) · Switzerland (2) · United Kingdom (2) · United States (2) · Denmark (1)
Results publications
PMID 39293462, PMID 40441170, PMID 40680993, PMID 42561994
NIH funding
2023 (2)